Emerging infectious diseases · 2008 · 312 citations · 15 references
Life SciencesInfectious DiseasesPharmacologyAntimicrobial ResistanceClinical PharmacologyInfectious Disease PharmacotherapyAntimicrobial Resistance ControlAntiparasitic Drug ResistanceAntiparasitic ResistanceDrug ResistanceMalariaMultidrug ResistanceAntimalarial AgentsAntimalarial Drug CombinationsAntimalarial Drug DevelopmentArtemisinin ResistanceChemotherapy Of MalariaMalaria ResistancePlasmodium FalciparumTreatment Of Malaria
Resistance to many antimalaria drugs developed on the Cambodia-Thailand border long before developing elsewhere. Because antimalaria resistance is now a global problem, artemisinin-based combination therapies (ACTs) are the first-line therapies in most malaria-endemic countries. However, recent clinical and molecular studies suggest the emergence of ACT-resistant Plasmodium falciparum infections in the Cambodia-Thailand border area, where standard ACT is artesunate and mefloquine. These ACT failures might be caused by high-level mefloquine resistance because mefloquine was used for monotherapy long before the introduction of ACT. This observation raises 2 questions. First, how can existing P. falciparum-resistant strains be controlled? Second, how can the evolution of new ACT- resistant strains be avoided elsewhere, e.g., in Africa? Enforcement of rational drug use and improved diagnostic capacity are among the measures needed to avoid and contain ACT resistance.
15
Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number
Ric N. Price, Anne‐Catrin Uhlemann, Alan Brockman et al. · The Lancet · 2004 · 839 citations
Amar Bir Singh Sidhu, Anne‐Catrin Uhlemann, Juan‐Carlos Valderramos et al. · The Journal of Infectious Diseases · 2006 · 407 citations · Full text